Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.45 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
| ▸ | RAMP3 | O60896 | 6/20 | 0.42 |
| ▸ | CALCR | P30988 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211041 | 0.90 | NMUR2 (0.53) | NMUR2NMUR1PLK1APLNRRAMP3 | |
| SCHEMBL30211030 | 0.90 | NMUR2 (0.53) | NMUR2NMUR1PLK1APLNRRAMP3 | |
| SCHEMBL30211011 | 0.89 | PLK1 (0.52) | NMUR2NMUR1PLK1APLNRRAMP3 | |
| SCHEMBL29496452 | 0.88 | PLK1 (0.44) | OPRM1OPRD1PLK1RAMP3CALCR | |
| SCHEMBL30493699 | 0.86 | NMUR2 (0.50) | NMUR2NMUR1OPRM1OPRD1APLNR | |
| SCHEMBL29496458 | 0.86 | NMUR2 (0.41) | NMUR2NMUR1OPRM1OPRD1APLNR | |
| SCHEMBL31489174 | 0.86 | NMUR2 (0.46) | NMUR2NMUR1PLK1APLNRRAMP3 | |
| SCHEMBL30658573 | 0.86 | NMUR2 (0.43) | NMUR2NMUR1OPRM1OPRD1PLK1 | |
| SCHEMBL30531335 | 0.86 | NMUR2 (0.42) | NMUR2NMUR1OPRM1OPRD1PLK1 | |
| SCHEMBL31257058 | 0.85 | PLK1 (0.40) | NMUR2NMUR1OPRM1OPRD1PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894611-A | Selenium-rich moringa seed ACE inhibitory peptide and application thereof | 北部湾大学 | 2023-04-04 | — | — | CN | disclosed |